3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Genitourinary
1
Conditions
Multiple Myeloma
51
Recurrence
5
Neoplasms, Plasma Cell
3
Immunoglobulin Light-chain Amyloidosis
3
Amyloidosis
2
Renal Insufficiency
1
Plasmablastic Lymphoma
1
Kidney Failure, Chronic
1
Interventions
Kidney Transplantation
3
Standard of Care
2
tocilizumab
1
peginesatide
1
orellanine
1
hematide
1
carfilzomib
1
belantamab mafodotin
1
Sitagliptin Phosphate
1
Practice Guidelines as Topic
1
Massage
1
Mass Screening
1
Immunoglobulin G
1
Duration of Therapy
1
Disulfides
1
Cyclosporine
1
Cyclophosphamide
1
Antilymphocyte Serum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Kidney Failure, Chronic
×
belantamab mafodotin
×
Clear all
NCT04398745
2025-05-23
DREAMM12
GlaxoSmithKline
Phase 1
Active not recruiting
36 enrolled